Related Party Transactions |
6 Months Ended | ||
|---|---|---|---|
Jun. 30, 2025 | |||
| Related Party Transactions [Abstract] | |||
| Related Party Transactions |
Jinzi J. Wu, Ph.D., a member of the Company’s board of directors until June 2024, founded and serves as the chief executive officer of Ascletis, Gannex, and Ascletis Pharma. During the six months ended June 30, 2024, the Company recognized $0.1 million of expenses under the Ascletis license agreement, inclusive of manufacturing services fees charged by Ascletis pursuant to the manufacturing agreement with Ascletis which falls under the license agreement. These expenses are recorded in research and development expense in the statements of operations and comprehensive loss.
|